

Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029

<https://marketpublishers.com/r/G0660F3A7A5FEN.html>

Date: March 2024

Pages: 1200

Price: US\$ 4,200.00 (Single User License)

ID: G0660F3A7A5FEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029 Report Highlights:

Bispecific Antibodies Development Proprietary Platforms Insight: > 30 Platforms

Global Bispecific Antibodies Market Size Yearly & Quarterly Sales (2018 till 2023)

Global Bispecific Antibodies Market Size 2023: > USD 8 Billion

Global Bispecific Antibodies Market Forecast Till 2029

Approved Bispecific Antibodies Yearly & Quarterly Sales (2018 till 2023)

Approved Bispecific Antibodies Regional Sales (2018 till 2023)

Clinical & Commercial Insight On Approved Bispecific Antibodies: 12 Antibodies

Approved Bispecific Antibodies Pricing & Dosage Analysis

Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase: > 800 Antibodies

FDA & EMA Fast Track Approval, Orphan Designation, Priority Status Insights

Bispecific antibodies represent an exciting new therapeutic approach that has been gaining momentum since the last decade. These meticulously designed molecules offer a unique mechanism of action that harnesses the immune system to target malignant and other diseased cells and tissues with precision, offering a targeted approach that minimizes the risk of adverse effects. In the last three years, the market of bispecific antibodies has experienced a rapid surge in research and development, and commercial activities, setting the market for a speedy growth in the coming years.

Bispecific antibodies are engineered proteins intended to simultaneously bind two different antigens, typically found on distinct cell types. Their dual targeting ability provides multiple ways to exploit the immune systems against diseases. For cancer, common approaches include redirecting T cells or natural killer cells to attack malignant cells. They can also crosslink immune cells with tumor cells to enhance the immune response. Additionally, they can block two different signaling pathways or recruit immune cells to the tumor microenvironment.

For indications apart from cancer, bispecific antibodies enable dual targeting of different disease mediators or cell types. This provides opportunities to neutralize or clear pathogenic proteins, cytokines or cells involved in inflammation, autoimmunity and other diseases. However, depending on the indications, the mechanism by which bispecific antibodies work can change.

The versatility of bispecific antibodies offers several advantages over their predecessors, traditional monoclonal antibodies, including enhanced specificity, potency and flexibility in targeting multiple pathways at the same time. This become especially relevant in cancer treatment, where monoclonal antibodies are utilized heavily to interfere with different cancer-associated pathways. By directly redirecting immune cells to tumors, bispecific antibodies can overcome tumor immune evasion mechanisms, leading to improved efficacy and potentially lower toxicity compared to conventional chemotherapy.

The US FDA approved Blinatumomab (commercially known as Blincyto) in 2014, marking a key milestone in the field of bispecific antibodies and fundamentally changing how relapsed or refractory precursor B-cell acute lymphoblastic leukemia is treated. Following this success, multiple new bispecific antibodies have arisen in clinical

development, covering a wide range of medical disorders, with a focus on cancer. Nonetheless, in addition to cancer, there has been an increase in the number of bispecific candidates designed to address emerging indications such as viral and bacterial infections, as well as autoimmune diseases. This diversification highlights the growing range of therapeutic applications for this class of medicines.

Currently, there are over 800 bispecific candidates in active clinical development. Phase 3 trials are underway across a spectrum of solid cancers like triple negative breast cancer, small cell lung cancer, bladder cancer among others, in addition to hematological cancers, including myeloma and leukemia. Further, a few other phase 3 candidates are also being investigated in indications beyond cancer, like hemophilia A and diabetic macular edema, displaying the diversity in indications.

The heightened attention on the development of this novel therapeutic class has been greatly supported by the increasing global value of the bispecific antibodies market. At present, 12 bispecific antibodies have received approvals in different markets around the globe, which together, generated revenue of over US\$ 8.5 Billion in the year 2023. This was an increase of over 47% as compared to the total sales of 2022, which was approximately over US\$ 5.8 Billion. A bulk of this value comes from the global sales of Hemlibra, a bispecific antibody indicated for the treatment of Hemophilia A, which is the highest selling member of this drug class.

Since bispecific antibodies were introduced in the market, the US has been a major contributor to the overall sales of these drugs. In 2023, the US market alone generated a revenue of US\$ 5.6 Billion, with the international market contributing US\$ 2.8 Billion to the total sales. This was an increase of 34% compared to the sales recorded in 2022, showing the growing interest of patients and physicians in novel therapeutics, such as bispecific antibodies.

Therefore, bispecific antibodies have demonstrated enough clinical success to validate their potential as a major new drug class. Their unique ability to tap into multiple disease pathways is unlocking new therapeutic possibilities beyond monoclonal antibodies. While oncology has led the way, expansion into other disease areas is accelerating. With continued innovation in molecular designs and engineering, bispecific antibodies represent an exciting versatile approach to transform treatment across a wide range of unmet medical needs, which researchers are slowly progressing to.

Contents

1. INTRODUCTION TO BISPECIFIC ANTIBODY

- 1.1 Overview
- 1.2 Clinical Advancement of Bispecific Antibodies

2. BISPECIFIC ANTIBODIES COMBINATION STRATEGIES

- 2.1 Chemotherapies
- 2.2 Targeted Therapies
- 2.3 Immunotherapies
- 2.4 Radiotherapy

3. COMMERCIALY APPROVED BISPECIFIC ANTIBODIES INSIGHT

- 3.1 Company, Indication, Location & MOA
- 3.2 Bispecific Antibodies Granted FDA & EMA Designations

4. BISPECIFIC ANTIBODIES PROPRIETARY PLATFORMS

5. GLOBAL & REGIONAL BISPECIFIC ANTIBODY MARKET OUTLOOK

- 5.1 Yearly & Quarterly Sales Insight (2019 to 2023)
- 5.2 Approved Bispecific Antibodies Reimbursement Policy
- 5.3 Global Bispecific Antibody Market Forecast 2029

6. GLOBAL BISPECIFIC ANTIBODY MARKET TRENDS BY REGION

- 6.1 US
- 6.2 Europe
- 6.3 China
- 6.4 UK
- 6.5 Japan
- 6.6 South Korea
- 6.7 Australia
- 6.8 Canada
- 6.9 Latin America

7. GLOBAL BISPECIFIC ANTIBODIES RESEARCH & MARKET TRENDS BY INDICATIONS

- 7.1 Lymphoma
- 7.2 Multiple Myeloma
- 7.3 Leukemia
- 7.4 Lung Cancer
- 7.5 Melanoma
- 7.6 Blood Disorders
- 7.7 Gastrointestinal Cancers
- 7.8 Other Cancers
- 7.9 Autoimmune & Inflammatory Diseases
- 7.10 Microbial Diseases
- 7.11 Ocular Diseases

8. GLOBAL BISPECIFIC ANTIBODIES CLINICAL TRIALS OVERVIEW

- 8.1 By Phase
- 8.2 By Country/Region
- 8.3 By Company
- 8.4 By Indication
- 8.5 By Priority Status
- 8.6 Patient Segment

9. BLINCYTO – CLINICAL, PATENT, PRICING & SALES INSIGHT

- 9.1 Overview & Patent Insight
- 9.2 Pricing & Dosage Analysis
- 9.3 Sales Analysis

10. HEMLIBRA - CLINICAL, PATENT, PRICING & SALES INSIGHT

- 10.1 Overview
- 10.2 Pricing & Dosage Insight
- 10.3 Sales Analysis

11. RYBREVANT - CLINICAL, PATENT & PRICING INSIGHT

- 11.1 Overview

11.2 Pricing & Dosage Insight

12. KIMMTRAK - CLINICAL, PATENT, PRICING & SALES INSIGHT

12.1 Overview

12.2 Pricing & Dosage Insight

12.3 Sales Analysis

13. VABYSMO - CLINICAL, PATENT, PRICING & SALES INSIGHT

13.1 Overview

13.2 Pricing & Dosage Insight

13.3 Sales Analysis

14. LUNSUMIO - CLINICAL, PATENT, PRICING & SALES INSIGHT

14.1 Overview & Patent Insight

14.2 Pricing & Dosage Insight

14.3 Sales Analysis

15. CADONILIMAB – CLINICAL & SALES INSIGHT

16. TECVAYLI - CLINICAL, PATENT & PRICING INSIGHT

16.1 Overview & Patent Insight

16.2 Pricing & Dosage Insight

17. COLUMVI - CLINICAL, PATENT, PRICING & SALES INSIGHT

17.1 Overview & Patent Insight

17.2 Pricing & Dosage Insight

17.3 Sales Analysis

18. EPKINLY - CLINICAL, PATENT, PRICING & SALES INSIGHT

18.1 Overview

18.2 Pricing & Dosage Insight

18.3 Sales Analysis

19. TALVEY - CLINICAL, PATENT & PRICING INSIGHT

19.1 Overview & Patent Insight

19.2 Pricing & Dosage Insight

20. ELREXFIO - CLINICAL, PATENT & PRICING INSIGHT

20.1 Overview

20.2 Pricing & Dosage Insight

21. GLOBAL BISPECIFIC ANTIBODIES CLINICAL TRIALS BY COMPANY, INDICATION & PHASE

21.1 Research

21.2 Preclinical

21.3 Phase-I

21.4 Phase-I/II

21.5 Phase-II

21.6 Phase-II/III

21.7 Phase-III

21.8 Preregistration

21.9 Registered

22. MARKETED BISPECIFIC ANTIBODIES CLINICAL INSIGHT BY COMPANY, COUNTRY & INDICATION

23. COMPETITIVE LANDSCAPE

23.1 ABL Bio

23.2 Abzyme Therapeutics

23.3 Affimed Therapeutics

23.4 Akeso Biopharma

23.5 Alligator Bioscience

23.6 Amgen

23.7 Antibody Therapeutics

23.8 APITBIO

23.9 Aptevo Therapeutics

23.10 Astellas Pharma

23.11 AstraZeneca

- 23.12 BioAtla
- 23.13 Biosion
- 23.14 Biotheus
- 23.15 BJ Bioscience
- 23.16 EpimAb Biotherapeutics
- 23.17 FutureGen Biopharmaceutical
- 23.18 Genentech
- 23.19 Genmab
- 23.20 Gensun Biopharma
- 23.21 Harbour BioMed
- 23.22 IGM Biosciences
- 23.23 I-MAB Biopharma
- 23.24 ImmuneOnco Biopharma
- 23.25 ImmunoPrecise Antibodies
- 23.26 Innovent Biologics
- 23.27 Invenra
- 23.28 Janssen Research & Development
- 23.29 Kenjockey Biotechnology
- 23.30 LaNova Medicines Limited
- 23.31 Light Chain Bioscience
- 23.32 Linton Pharm
- 23.33 Lyvgen Biopharma
- 23.34 MacroGenics
- 23.35 Merus
- 23.36 NovaRock Biotherapeutics
- 23.37 Pfizer
- 23.38 Phanes Therapeutics
- 23.39 Prestige BioPharma
- 23.40 Regeneron Pharmaceuticals
- 23.41 Revitope
- 23.42 Roche
- 23.43 Virtuoso Therapeutics
- 23.44 Xencor
- 23.45 Y-Biologics
- 23.46 Zhejiang Shimai Pharmaceutical
- 23.47 Zymeworks

List Of Figures

LIST OF FIGURES

- Figure 1-1: Bispecific Antibodies - Advantages
- Figure 2-1: Antibody-Chemotherapy Combination - Advantages
- Figure 2-2: Antibody-Chemotherapy Combination – Impending Challenges
- Figure 3-1: Blincyto - Mechanism of Action
- Figure 3-2: Hemlibra - Mechanism of Action
- Figure 3-3: Rybrevant - Mechanism of Action
- Figure 3-4: Regulatory Designations - Benefits
- Figure 4-1: Multiclonics - Distinctive Characteristics
- Figure 4-2: Biclomics - Format
- Figure 4-3: ADAPTIR Bispecific Structure
- Figure 4-4: ADAPTIR-FLEX
- Figure 4-5: BEAT Platform - Multispecific Antibodies
- Figure 4-6: FIT-Ig - Proprietary Bispecific Platform
- Figure 4-7: BiClone format
- Figure 4-8: BioAtla CABs – Features
- Figure 4-9: BioAtla CABs – Benefits
- Figure 4-10: IMBiologic Bispecific Antibodies - Strategy
- Figure 4-11: IMBiologic Bispecific Antibodies – Mechanism of Action
- Figure 4-12: Novel HBICE
- Figure 4-13: HBICE - Mechanism of Action
- Figure 4-14: HBICE - Mechanism of Action
- Figure 4-15: Phanes Therapeutics – PACbody Platform
- Figure 4-16: Phanes Therapeutics – SPECpair Platform
- Figure 4-17: Phanes Therapeutics – ATACCbody
- Figure 4-18: Numab Therapeutics - Technology
- Figure 4-19: Grabody I Platform - Mechanism of Action
- Figure 4-20: Grabody I Platform - Mechanism of Action
- Figure 4-21: 3-Step DuoBody Production Process
- Figure 4-22: DuoHexaBody Molecules – Schematic
- Figure 4-23: iTAb – Patented Structure
- Figure 4-24: iTAb – Mechanism of Action
- Figure 4-25: Synimmune - Proprietary Bispecific Antibody Format
- Figure 4-26: BiTE - Structure
- Figure 4-27: BiTE Molecule
- Figure 4-28: Sanyou Super Trillion Common Light Chain Antibody Discovery Platform

Figure 4-29: ALiCE – Characteristics

Figure 4-30: ALiCE - Schematic Diagram & Mechanism of Action

Figure 4-31: Abz2 Bispecific Platform

Figure 4-32: Abz2 Bispecifics - Benefits

Figure 4-33: Neo-X-Prime Bispecific Mechanism

Figure 4-34: B-Body Bispecific Antibody - Structure

Figure 4-35: xLinkBsAb - Structure

Figure 4-36: PrecisionGATE Bispecific Antibody – Structure

Figure 5-1: Global – Annual Bispecific Antibody Market (US\$ Million), 2019-2023

Figure 5-2: Global – Quarterly Bispecific Antibody Market (US\$ Million), 2023

Figure 5-3: Global - Annual Bispecific Antibodies Market by Drug (US\$ Million), 2023

Figure 5-4: Global - Bispecific Antibodies Market Shares by Drugs (%), 2023

Figure 5-5: Global - Annual Bispecific Antibody Market by Region (US\$ Billion), 2023

Figure 5-6: Global – Bispecific Antibody Market Shares by Region (%), 2023

Figure 5-7: Global – Annual Bispecific Antibodies Sales by Drugs (US\$ Million), 2022

Figure 5-8: Global - Bispecific Antibodies Market Shares by Drugs (%), 2022

Figure 5-9: Global - Bispecific Antibody Market by Region (US\$ Million), 2022

Figure 5-10: Global - Bispecific Antibody Market Shares by Region (%), 2022

Figure 5-11: US – Annual Bispecific Antibody Market Value (US\$ Million), 2019-2023

Figure 5-12: ROW – Global Bispecific Antibody Market Value (US\$ Million), 2019-2023

Figure 5-13: US - Quarterly Bispecific Antibodies Market (US\$ Million), 2023

Figure 5-14: ROW - Quarterly Bispecific Antibodies Market (US\$ Million), 2023

Figure 5-15: Blincyto - Total Treatment Cost & Reimbursement Cost

Figure 5-16: Blincyto – In Pocket & Out of Pocket Cost of Treatment

Figure 5-17: Hemlibra - Total Treatment Cost & Reimbursement Cost

Figure 5-18: Hemlibra – In Pocket & Out of Pocket Cost of Treatment

Figure 5-19: Rybrevant - Maximum Coverage by Medicaid (US\$), 2023

Figure 5-20: Rybrevant - Maximum Coverage by Private Insurance Coverage (US\$), 2021

Figure 5-21: Vabysmo - Total Treatment Cost & Reimbursement Cost

Figure 5-22: Vabysmo – In Pocket & Out of Pocket Cost of Treatment

Figure 5-23: Global - Bispecific Antibody Market Opportunity Assessment (US\$ Billion), 2024 – 2029

Figure 6-1: US – Bispecific Antibodies Approval

Figure 6-2: Blincyto - US v/s ROW Sales (US\$ Million), 2023

Figure 6-3: Blincyto - US v/s ROW Shares (%), 2023

Figure 6-4: Blincyto - US v/s ROW Sales (US\$ Million), 2022

Figure 6-5: Blincyto - US v/s ROW Shares (%), 2022

Figure 6-6: Hemlibra - US v/s ROW Sales (US\$ Million), 2023

- Figure 6-7: Hemlibra – US v/s ROW Shares (%), 2023
- Figure 6-8: Hemlibra - US v/s ROW Sales (US\$ Million), 2022
- Figure 6-9: Hemlibra - US v/s ROW Shares (%), 2022
- Figure 6-10: Global – US v/s ROW in Bispecific Antibodies Market (US\$ Million), 2023
- Figure 6-11: Global – US v/s ROW Shares in Bispecific Antibodies Market (%), 2023
- Figure 6-12: Global – US v/s ROW in Bispecific Antibodies Market (US\$ Million), 2022
- Figure 6-13: Global – US v/s ROW Shares in Bispecific Antibodies Market (%), 2022
- Figure 6-14: Blincyto – US Patent Filing & Expiration Year
- Figure 6-15: Blincyto – EU Patent Expiration
- Figure 6-16: Vabysmo – Canada Patent Numbers Expiration & Approval Year
- Figure 6-17: Hemlibra – Canada Patent Numbers Approval & Expiration Year
- Figure 6-18: Rybrevant – Canada Patent Numbers Approval & Expiration Year
- Figure 6-19: Kimmtrak – Canada Patent Number Approval & Expiration Year
- Figure 7-1: Bispecific Antibodies - Advantages
- Figure 7-2: TG-1801 Phase 1 Study – Initiation & Completion Year
- Figure 7-3: Bispecific Antibodies – Future Opportunities
- Figure 7-4: Mim8 Phase 3 (NCT05053139) Study – Initiation & Completion Year
- Figure 7-5: Mim8 Phase 3 (NCT05878938) Study – Initiation & Completion Year
- Figure 7-6: NXT007 Phase 1/2 (NCT05987449) Study – Initiation & Completion Year
- Figure 7-7: HMB-001 Phase 1/2 (NCT06211634) Study – Initiation & Completion Year
- Figure 7-8: REGN4018 Phase 1/2 (NCT03564340) Study – Initiation & Completion Year
- Figure 7-9: PRV-3279 Phase 2 (NCT05087628) Study – Initiation & Completion Year
- Figure 8-1: Global - Bispecific Antibodies Clinical Pipeline by Phase (Numbers), 2023
- Figure 8-2: Global - Bispecific Antibodies in Clinical Pipeline by Country (Numbers), 2024 till 2029
- Figure 8-3: Global - Bispecific Antibodies in Clinical Pipeline by Company (Numbers), 2024 till 2029
- Figure 8-4: Global - Bispecific Antibodies in Clinical Pipeline by Indication (Numbers), 2023 till 2029
- Figure 8-5: Global - Bispecific Antibodies in Clinical Pipeline by Orphan Status (Numbers), 2023 till 2029
- Figure 8-6: Global - Bispecific Antibodies in Clinical Pipeline by Patient Segment (Numbers), 2023 till 2029
- Figure 9-1: Blincyto – Approval Year by Region
- Figure 9-2: Blincyto – Patent Filing & Expiration Year
- Figure 9-3: Blincyto - Treatment Regimen Cycles (Weeks)
- Figure 9-4: Blincyto – Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD-Positive B-cell precursor (Days)
- Figure 9-5: Blincyto - Cost of Single Cycle & Treatment Course for the Treatment of

MRD-positive B-cell Precursor ALL

Figure 9-6: Blincyto – Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL

Figure 9-7: Blincyto – Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)

Figure 9-8: Blincyto - Cost of Single Cycle & Treatment Course for Treatment for Relapsed B-Cell Precursor ALL

Figure 9-9: Global – Blincyto Sales (US\$ Million), 2019–2023

Figure 9-10: Global – Blincyto Sales (US\$ Million), Q1 – Q4'2023

Figure 9-11: Blincyto - US v/s ROW Sales (US\$ Million), 2023

Figure 9-12: Global – Blincyto Sales by Region (%), 2023

Figure 9-13: US – Blincyto Sales (US\$ Million), Q1 – Q4'2023

Figure 9-14: ROW – Blincyto Sales (US\$ Million), Q1 – Q4'2023

Figure 9-15: US – Blincyto Sales ((US\$ Million), 2019-2023

Figure 9-16: ROW – Blincyto Sales (US\$ Million), 2019-2023

Figure 10-1: Hemlibra – Approval Years by Region

Figure 10-2: Hemlibra – Cost per Unit & Supply of 150 mg/mL Subcutaneous Injection (US\$), February'2024

Figure 10-3: Hemlibra – Recommended Loading & Maintenance Dose for Treatment of Hemophilia (mg/kg/Week)

Figure 10-4: Global – Hemlibra Sales (US\$ Million), 2019-2023

Figure 10-5: US – Hemlibra Sales (US\$ Million), 2019-2023

Figure 10-6: Europe – Hemlibra Sales (US\$ Million), 2019-2023

Figure 10-7: Japan – Hemlibra Sales (US\$ Million), 2019-2023

Figure 10-8: ROW – Hemlibra Sales (US\$ Million), 2019-2023

Figure 10-9: Global – US v/s ROW Sales (US\$ Million), 2023

Figure 10-10: Global – Hemlibra Annual Sales by Region (US\$ Million), 2023

Figure 10-11: Global – Hemlibra Sales by Region (%), 2023

Figure 10-12: Global – Hemlibra Sales (US\$ Million), Q1 – Q4'2023

Figure 10-13: US – Hemlibra Sales (US\$ Million), Q1 – Q4'2023

Figure 10-14: Europe – Hemlibra Sales (US\$ Million), Q1 – Q4'2023

Figure 10-15: Japan – Hemlibra Sales (US\$ Million), Q1 – Q4'2023

Figure 10-16: ROW – Hemlibra Sales (US\$/ US\$ Million), Q1 – Q4'2023

Figure 11-1: Rybrevant – Price per Unit & Supply of Intravenous Solution (US\$), February'2024

Figure 11-2: Rybrevant – Recommended Dose Per Cycle by Body Weight (mg)

Figure 11-3: Rybrevant – Dose Reduction in Patients with Weight less than 80 kg (mg)

Figure 11-4: Rybrevant – Dose Reduction in Patients with Weight more than 80 Kg (mg)

Figure 12-1: Kimmtrak – Approval Year by Region

- Figure 12-2: Kimmtrak – Cost Per Unit & Per Vial (US\$), February'2024
- Figure 12-3: Global – Annual Kimmtrak Sales (US\$ Million), 2021-2023
- Figure 12-4: Global – Quarterly Kimmtrak Sales (US\$ Million), 2023
- Figure 12-5: Kimmtrak – Sales by Region (US\$ Million), 2023
- Figure 12-6: Kimmtrak – US v/s ROW Market Shares (US\$ Million), 2023
- Figure 12-7: Kimmtrak – US v/s ROW Market Shares (%), 2023
- Figure 12-8: US – Quarterly Kimmtrak Sales (US\$ Million), 2023
- Figure 12-9: EU – Quarterly Kimmtrak Sales (US\$ Million), 2023
- Figure 12-10 ROW – Quarterly Kimmtrak Sales (US\$ Million), 2023
- Figure 13-1: Vabysmo – Approval Year by Region
- Figure 13-2: Vabysmo – Price per Unit & Supply of Intravitreal Solution (US\$), February'2024
- Figure 13-3: Global – Vabysmo Sales (US\$ Million), 2022-2023
- Figure 13-4: Global – Vabysmo US v/s ROW Sales (US\$ Million), 2023
- Figure 13-5: Global – Vabysmo Annual Sales by Region (US\$ Million), 2023
- Figure 13-6: Global – Vabysmo Annual Sales by Region (%), 2023
- Figure 13-7: US – Vabysmo Sales (US\$ Million), 2022-2023
- Figure 13-8: Europe – Vabysmo Sales (US\$ Million), 2022-2023
- Figure 13-9: Japan – Vabysmo Sales (US\$ Million), 2022-2023
- Figure 13-10: ROW – Vabysmo Sales (US\$ Million), 2022-2023
- Figure 13-11: Global – Vabysmo Sales (US\$ Million), Q1 – Q4'2023
- Figure 13-12: US – Vabysmo Sales (US\$ Million), Q1 – Q4'2023
- Figure 13-13: Europe – Vabysmo Sales (US\$ Million), Q1 – Q4'2023
- Figure 13-14: Japan – Vabysmo Sales (US\$ Million), Q1 – Q4'2023
- Figure 13-15: ROW – Vabysmo Sales (US\$ Million), Q1 – Q4'2023
- Figure 14-1: Lunsumio – Approval Years by Region
- Figure 14-2: US – Price per Unit & Supply of Lunsumio Intravenous Solution (US\$), February'2024
- Figure 14-3: EU – Price per Unit & Supply of Lunsumio Intravenous Solution (US\$), February'2024
- Figure 14-4: Global – Lunsumio Sales (US\$ Million), 2022-2023
- Figure 14-5: US – Lunsumio Sales (US\$ Million), 2022-2023
- Figure 14-6: Europe – Lunsumio Sales (US\$ Million), 2022-2023
- Figure 14-7: Global – Lunsumio Annual Sales by Region (US\$ Million), 2023
- Figure 14-8: Global – Lunsumio Annual Sales by Region (%), 2023
- Figure 14-9:– Global - Lunsumio Sales (US\$ Million), Q1 – Q4'2023
- Figure 14-10: US – Lunsumio Sales (US\$ Million), Q1 – Q4'2023
- Figure 14-11: Europe – Lunsumio Sales (US\$ Million), Q1 – Q4'2023
- Figure 15-1: Annual – Cadonilimab Sales (US\$ Million), H2'2022 & H1'2023

Figure 16-1: Tecvayli – Approval Years by Region

Figure 16-2: Tecvayli – Patent Acceptance & Expiration Years

Figure 16-3: US – Cost per Unit & Supply of Tecvayli Subcutaneous Solution (US\$), February'2024

Figure 16-4: EU - Cost per Unit & Supply of Tecvayli Subcutaneous Solution (US\$), February'2024

Figure 17-1: Columvi – Approval Year by Region

Figure 17-2: US – Price per Unit & Supply of Columvi Intravenous Solution (US\$), February'2024

Figure 17-3: EU – Price per Unit & Supply of Columvi Intravenous Solution (US\$), February'2024

Figure 17-4: Global – Columvi Sales by Region (US\$ Million), 2023

Figure 17-5: Global – Columvi Sales (US\$ Million), Q1 – Q4'2023

Figure 17-6: US – Columvi Sales (US\$ Million), Q1 – Q4'2023

Figure 17-7: Europe – Columvi Sales (US\$ Million), Q1 – Q4'2023

Figure 18-1: Epkinly – Approval Year by Region

Figure 18-2: US - Cost per Unit & Supply of Epkinly Subcutaneous Solution (US\$), February'2024

Figure 18-3: EU - Cost per Unit & Supply of Epkinly Subcutaneous Solution (US\$), February'2024

Figure 18-4: Global – Epkinly Sales (US\$ Million), 2023

Figure 18-5: Global – Epkinly Sales (US\$ Million), Q1 – Q4'2023

Figure 19-1: Talvey – Approval Year by Region

Figure 19-2: Talquetamab – FDA & EMA Designation Year

Figure 19-3: Talvey – Patent Acceptance & Expiration Year

Figure 19-4: US – Price per Unit & Supply of Talvey Intravenous Solution (US\$), February'2024

Figure 19-5: EU – Price per Unit & Supply of Talvey Intravenous Solution (US\$), February'2024

Figure 20-1: Elrexfio – Approval Years by Region

Figure 20-2: Elranatamab – FDA & EMA Designation Years

Figure 20-3: US – Price per Unit & Supply of Elrexfio Subcutaneous Solution (US\$), February'2024

List Of Tables

LIST OF TABLES

- Table 2-1: Bispecific Antibody & Chemotherapy Combinations in Clinical Trials
- Table 2-2: Bispecific Antibody & Targeted Therapy Combinations in Clinical Trials
- Table 2-3: Bispecific Antibody & Immunotherapy Combinations in Clinical Trials
- Table 2-4: Bispecific Antibody & Radiotherapy Combinations in Clinical Trials
- Table 3-1: Approved Bispecific Antibodies
- Table 3-2: US - Bispecific Antibodies with Regulatory Designations
- Table 3-3: EU - Bispecific Antibodies with Regulatory Designations
- Table 3-4: EU - Bispecific Antibodies with Regulatory Designations
- Table 5-1: Epkinly - Billing Unit Application for Doses
- Table 5-2: Talvey - Coverage Summary
- Table 5-3: Talvey - Coding Summary
- Table 5-4: Elrexfio - HCPCS Codes
- Table 5-5: Elrexfio - HCPCS modifiers
- Table 6-1: US – FDA IND Applications Accepted, February’2024
- Table 6-2: EU - Bispecific Antibodies in Late Stage Clinical Trials
- Table 6-3: Bispecific Antibodies in Clinical Trials in Latin America
- Table 7-1: Lymphoma - Bispecific Antibodies in Clinical Trials
- Table 7-2: Multiple Myeloma - Bispecific Antibodies in Clinical Trials
- Table 7-3: Leukemia - Bispecific Antibodies in Clinical Trials
- Table 7-4: Lung Cancer - Bispecific Antibodies in Clinical Trials
- Table 7-5: Melanoma - Bispecific Antibodies in Clinical Trials
- Table 7-6: Digestive System Cancers - Bispecific Antibodies in Clinical Trials
- Table 7-7: Breast Cancer - Bispecific Antibodies in Clinical Trials
- Table 7-8: Gynecological Cancers - Bispecific Antibodies in Clinical Trials
- Table 7-9: Gynecological Cancers - Bispecific Antibodies in Clinical Trials
- Table 9-1: Blincyto – Active Patents
- Table 9-2: Blincyto - Recommended Dosage & Schedule for the Treatment of MRD-positive B-cell Precursor ALL
- Table 9-3: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
- Table 9-4: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
- Table 11-1: Rybrevant – Premedication
- Table 11-2: Rybrevant - Dose Reductions for Adverse Reactions
- Table 11-3: Rybrevant - Recommended Dosage Modifications for Adverse Reactions

Table 12-1: Kimmtrak - Recommended Dosage for Treatment of Unresectable or Metastatic Uveal Melanoma

Table 12-2: Kimmtrak - Dose Modifications for Adverse Reactions

Table 14-1: Lunsumio – Recommended Treatment Cycles

Table 14-2: Lunsumio - Recommended Premedications

Table 14-3: Lunsumio - Recommendations for Management of Cytokine Release Syndrome

Table 16-1: Tecvayli - Dosing Schedule

Table 16-2: Tecvayli - Recommended Dosage Modifications for Adverse Reactions

Table 17-1: Columvi - Dosing Schedule (21-Day Treatment Cycles)

Table 17-2: Columvi - Premedications to be Administered

Table 17-3: Columvi - Recommendations for Management of Cytokine Release Syndrome

Table 17-4: Columvi - Recommended Dosage Modification for Neurologic Toxicity (Including ICANS)

Table 17-5: Columvi - Recommended Dosage Modifications for Other Adverse Reactions

Table 18-1: Epkinly - Dosage Schedule

Table 18-2: Epkinly - Recommendations for Management of Cytokine Release Syndrome

Table 18-3: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Table 18-4: Epkinly - Recommended Dosage Modifications for Other Adverse Reactions

Table 19-1: Talvey - Weekly Dosing Schedule

Table 19-2: Talvey – Biweekly Dosing Schedule

Table 19-3: Talvey - Recommendations for Management of CRS

Table 19-4: Talvey - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Table 19-5: Talvey - Recommendations for Management of Neurologic Toxicity (excluding ICANS)

Table 19-6: Talvey - Recommended Dosage Modifications for Other Adverse Reactions

Table 20-1: Elrexfio - Dosing Schedule

Table 20-2: Elrexfio – Recommendations for Management of CRS

Table 20-3: Elrexfio - Recommended Dosage Modifications for Other Adverse

I would like to order

Product name: Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029

Product link: <https://marketpublishers.com/r/G0660F3A7A5FEN.html>

Price: US\$ 4,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0660F3A7A5FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

